Pharmaceutical intermediates
Apixaban Intermediates
6 pharmaceutical intermediates for Apixaban. Indication: Pulmonary Embolism; Venous Thrombosis; Venous Thromboembolism ; Thrombosis; Embolism; Stroke.
About Apixaban
- Originator
- Bristol Myers Squibb
- Indication
- Pulmonary Embolism; Venous Thrombosis; Venous Thromboembolism ; Thrombosis; Embolism; Stroke
- Approved Date
- 12/28/2012
- DS/DP
- 11/21/2026
Available intermediates
6 intermediates currently listed for Apixaban. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 3-Chloro-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one | 536760-29-9 | / | / |
| 3-Morpholino-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one | 503615-03-0 | / | / |
| 1-(4-Aminophenyl)-3-morpholino-5,6-dihydropyridin-2(1H)-one | 1267610-26-3 | / | / |
| 3-Morpholino-1-[4-(2-oxopiperidin-1-yl)phenyl]-5,6-dihydropyridin.2(1H)-one | 545445-44-1 | / | / |
| Ethyl chloro[(4-methoxyphenyl)hydrazono]acetate | 27143-07-3 | / | / |
| 1-(4-Methoxyphenyl)-7-0xo-6-[4-(2-0xopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acidethyl ester | 503614-91-3 | / | / |
Building toward Apixaban?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →